Overview

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This phase I trial tests the safety, side effects, and best dose of ZEN003694 and Binimetinib in treating patients with solid tumors that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable) with RAS alterations. ZEN003694 and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ZEN003694 and binimetinib together may help shrink or stabilize cancer.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)